Telesis Bio. has been granted a patent for a method of synthesizing DNA molecules with specific sequences. The process involves annealing long and short oligonucleotides to anchor strands, followed by ligation and amplification, enabling the creation of diverse DNA sequences without solid-phase binding. GlobalData’s report on Telesis Bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Telesis Bio, was a key innovation area identified from patents. Telesis Bio's grant share as of July 2024 was 62%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for synthesizing dna molecules with defined sequences
The patent US12065684B2 outlines a method for synthesizing a product DNA molecule with a specific sequence through a series of defined steps. The process begins with the annealing of long and short oligonucleotides to anchor strands that are partially complementary to them. This involves two primary configurations: one where two long oligonucleotides and two short oligonucleotides are used with two anchor strands, and another where two long oligonucleotides and one short oligonucleotide are utilized with a single anchor strand. Following the annealing, the method includes ligation of the oligonucleotides to form double-stranded DNA molecules, which are then subjected to enzymatic degradation to create single-stranded DNA. The final steps involve amplification of the DNA and the use of a Type IIS restriction endonuclease to synthesize the desired product DNA molecule.
The claims further specify variations in the oligonucleotides and anchor strands, including the incorporation of variable and degenerate nucleotides. The method allows for the synthesis of DNA molecules that can encode specific sequences, including guide RNAs and non-genetic messages. Additionally, the patent describes the use of an oligonucleotide library to select the necessary components for synthesis, ensuring a high degree of specificity and efficiency. The resulting product DNA molecule is characterized by a low error rate and can be designed to be scarless, meaning it does not leave unwanted sequences after synthesis. Overall, this patent presents a comprehensive approach to DNA synthesis that could have significant applications in genetic engineering and biotechnology.
To know more about GlobalData’s detailed insights on Telesis Bio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.